WallStSmart

Becton Dickinson and Company (BDX)vsMeihua International Medical Technologies Co Ltd (MHUA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 24383% more annual revenue ($21.92B vs $89.55M). MHUA leads profitability with a 10.3% profit margin vs 8.0%. MHUA trades at a lower P/E of 0.3x. BDX earns a higher WallStSmart Score of 61/100 (C+).

BDX

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 5.5Value: 10.0Quality: 6.5
Piotroski: 6/9Altman Z: 1.49

MHUA

Avoid

34

out of 100

Grade: F

Growth: 2.0Profit: 5.5Value: 8.3Quality: 8.5
Piotroski: 2/9Altman Z: 5.83
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+36.9%)

Margin of Safety

+36.9%

Fair Value

$286.42

Current Price

$158.27

$128.15 discount

UndervaluedFair: $286.42Overvalued
MHUAUndervalued (+96.4%)

Margin of Safety

+96.4%

Fair Value

$210.80

Current Price

$7.61

$203.19 discount

UndervaluedFair: $210.80Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX3 strengths · Avg: 8.3/10
Market CapQuality
$56.49B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

MHUA4 strengths · Avg: 10.0/10
P/E RatioValuation
0.3x10/10

Attractively priced relative to earnings

Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.8310/10

Safe zone — low bankruptcy risk

Areas to Watch

BDX4 concerns · Avg: 3.3/10
P/E RatioValuation
25.5x4/10

Moderate valuation

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

MHUA4 concerns · Avg: 2.8/10
Market CapQuality
$425.43M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
5.9%3/10

ROE of 5.9% — below average capital efficiency

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Revenue GrowthGrowth
-16.2%2/10

Revenue declined 16.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.

Bull Case : MHUA

The strongest argument for MHUA centers on P/E Ratio, Price/Book, Debt/Equity.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : MHUA

The primary concerns for MHUA are Market Cap, Return on Equity, Piotroski F-Score.

Key Dynamics to Monitor

BDX profiles as a value stock while MHUA is a declining play — different risk/reward profiles.

MHUA carries more volatility with a beta of 0.75 — expect wider price swings.

BDX is growing revenue faster at 1.6% — sustainability is the question.

BDX generates stronger free cash flow (549M), providing more financial flexibility.

Bottom Line

BDX scores higher overall (61/100 vs 34/100). MHUA offers better value entry with a 96.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Meihua International Medical Technologies Co Ltd

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Meihua International Medical Technologies Co., Ltd. is engaged in the manufacturing and marketing of medical consumables in the People's Republic of China.

Visit Website →

Want to dig deeper into these stocks?